

**AMENDMENTS TO THE CLAIMS**

This listing replaces all prior versions and listings of claims in the application.

**Listing of Claims**

1-60. (Cancelled)

61. (Currently amended) A kit for ~~detecting the presence of at least one biomarker indicative of diagnosing~~ intra-amniotic inflammation, ~~in a sample of amniotic fluid~~ comprising:

~~one or more adsorbents at least one adsorbent that binds collectively bind at least one biomarker associated with intra-amniotic inflammation biomarkers HNP-1, HNP-2, calgranulin A and calgranulin C and~~

~~instructions for mixing said adsorbent adsorbents with a sample of amniotic fluid, and monitoring said mixture for binding between said adsorbent and a biomarker each of said biomarkers in said sample, and correlating the presence of one or more of the biomarkers with intra-amniotic inflammation~~

~~wherein said kit includes at least one adsorbent that detects a calgranulin.~~

62. (Currently amended) A kit as claimed in claim 61, wherein said adsorbent is an antibody ~~is immobilized on a solid substrate~~.

63. (Currently amended) A kit as claimed in claim 62, which additionally comprises an enzyme-antibody conjugate ~~used to detect biomarker immobilized on said solid substrate~~.

64. (Currently amended) A kit as claimed in claim 61, wherein said ~~solid substrate is a adsorbent is immobilized on a probe~~.

65. (Previously presented) A kit as claimed in claim 64, wherein said kit instructions specify analysis by laser desorption/ionization mass spectrometry.

66. (Cancelled)

67. (Currently amended) A kit as claimed in claim ~~66~~ **64**, wherein said adsorbent is a hydrophobic adsorbent.

68. (Currently amended) A kit as claimed in 67, wherein said ~~probe is a Ciphergen H4 probe or H50 probe adsorbent comprises a C9 aliphatic chain attached to a phenyl ring or a C16 aliphatic chain.~~

69-76. (Cancelled)

77. (Currently amended) A method for qualifying the risk of preterm delivery in a pregnant patient, ~~comprised of comprising~~ analyzing a sample of amniotic fluid from said patient for ~~a level of at least one calgranulin the presence of each of at least biomarkers HNP-1, HNP-2, calgranulin A and calgranulin C and correlating the presence of one or more of the biomarkers with a risk of preterm delivery.~~

78-81. (Cancelled)

82. (Currently amended) A method for qualifying the risk of preterm delivery in a pregnant patient, comprising

(A) providing a spectrum generated by subjecting a sample of amniotic fluid from said patient to mass spectroscopic analysis that includes profiling on a biologically- or chemically- derivatized affinity surface

and

(B) putting said spectrum through pattern-recognition analysis that is keyed to at least ~~one peak peaks~~ indicative of the presence of a ~~HNP-1, HNP-2, calgranulin A and calgranulin C~~ in said sample.

83-89. (Cancelled)

90. (Previously presented) A method according to claim 82, wherein said patient does not have a white blood cell count that is elevated out of the normal range.

91. (New) A method for diagnosing intra-amniotic inflammation in a patient, comprising analyzing a sample of amniotic fluid from a patient for the presence of each of at least biomarkers HNP-1, HNP-2, calgranulin A and calgranulin C and correlating the presence of one or more of the biomarkers with intra-amniotic inflammation.